0
0

Chapter 38. Gabapentin and Pregabalin

Mark A. Frye, M.D.; Katherine Marshall Moore, M.D.
DOI: 10.1176/appi.books.9781585623860.414338

Sections

Excerpt

Anticonvulsants have long been used in the treatment of certain psychiatric conditions. As exemplified by the U.S. Food and Drug Administration (FDA) indications for divalproex sodium, carbamazepine, and lamotrigine in the acute and maintenance phases of bipolar disorder (Yatham et al. 2002), anticonvulsants are widely viewed as valid alternatives to, and in some cases preferred over, the conventional first-line psychopharmacotherapy choices of lithium and antipsychotics. Early observations of enhanced general well-being in epileptic patients treated with anticonvulsants, as well as various early hypotheses of kindling and sensitization proposed as models of affective illness progression (Weiss and Post 1998), have promoted controlled investigations of anticonvulsant drugs as potential mood-stabilizing agents.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Arnold LM, Crofford LJ, Martin SA, et al: The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Medicine 8:633–638, 2007
[PubMed]
 
Backonja M, Beydoun A, Edwards KR, et al: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280:1831–1836, 1998
[PubMed]
 
Becker HC, Myrick H, Veatch LM: Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol 4:399–406, 2006
 
Beydoun A, Fakhoury T, Nasreddine W, et al: Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 39:188–193, 1998
[PubMed]
 
Bonnet U, Banger M, Leweke FM, et al: Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol 23:514–519, 2003
[PubMed]
 
Bonnet U, Specka M, Leweke FM, et al: Gabapentin's acute effect on mood profile—a controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 31:434–438, 2007
[PubMed]
 
Bozikas V, Petrikis P, Gamvrula K, et al: Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry 26:197–199, 2002
[PubMed]
 
Cora-Locatelli G, Greenburg BD, Martin JD, et al: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 59:480–481, 1998
[PubMed]
 
Crofford LJ, Rowbotham MC, Mease PJ, et al: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Pregabalin 1008–105 Study Group. Arthritis Rheum 52:1264–1273, 2005
[PubMed]
 
Crofford LJ, Mease PJ, Simpson SL, et al: Fibromyalgia Relapse Evaluation and Efficacy for Durability Of Meaningful Relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136:419–431, 2008
[PubMed]
 
Dimond KR, Pande AC, Lamoreaux L, et al: Effect of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 20:407–417, 1996
[PubMed]
 
Dooley DJ, Donovan CM, Meder WP, et al: Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 45:171–190, 2002
[PubMed]
 
Dworkin RH, Corbin AE, Young JP, et al: Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60:1274–1283, 2003
[PubMed]
 
Elger CE, Brodie MJ, Anhut H, et al: Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46:1926–1935, 2005
[PubMed]
 
Freeman R, Durso-Decruz E, Emir B: Efficacy, safety, and tolerability of pregabalin treatment of painful diabetic peripheral neuropathy: findings from 7 randomized controlled trials across a range of doses. Diabetes Care 31:1448–1454, 2008
[PubMed]
 
Freynhagen R, Strojek K, Griesing T, et al: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week randomized, double-blind, multicentre, placebo-controlled trial of flexible and fixed dose regimens. Pain 115:254–263, 2005
[PubMed]
 
Frye MA, Kimbrell TA, Dunn RT, et al: Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol 18:461–464, 1998
[PubMed]
 
Frye MA, Ketter TA, Kimbrell TA, et al: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607–614, 2000
[PubMed]
 
Furieri FA, Nakamura-Palacios EM: Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 11:1691–1700, 2007
 
Gerner RH, Fairbanks L, Anderson GM, et al: Plasma levels of GABA and panic disorder. Psychiatry Res 63:223–225, 1996
 
Gold BI, Bowers MB, Roth RH, et al: GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 137:362–364, 1980
[PubMed]
 
Goldlust A, Su T, Welty DF, et al: Effects of the anticonvulsant drug gabapentin on enzymes in the metabolic pathways of glutamate and GABA. Epilepsy Res 22:1–11, 1995
[PubMed]
 
Grunze H, Dittert S, Bungert M, et al: Renal impairment as a possible side effect of gabapentin: a single case report. Neuropsychobiology 38:198–199, 1998
[PubMed]
 
Hamandi K, Sander JW: Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 15:73–78, 2006
[PubMed]
 
Hutson SM, Berkich D, Drown P, et al: Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism. J Neurochem 71:863–874, 1998
[PubMed]
 
Karam-Hage M, Brower KJ: Open pilot study of gabapentin versus trazodone to treatment insomnia in alcoholic outpatients. Psychiatry Clin Neurosci 57:542–544, 2003
[PubMed]
 
Kavoussi R: Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 16:S128–S133, 2006
 
Leweke FM, Bauer J, Elger CE: Manic episode due to gabapentin treatment. Br J Psychiatry 175:291, 1999
[PubMed]
 
Loscher W, Honack D, Taylor CP: Gabapentin increased aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett 128:150–154, 1991
[PubMed]
 
Pfizer: Lyrica (pregabalin) tablets: prescribing information. New York, Pfizer, 2006
 
Mahmood T, Romans S, Silverstone T: Prevalence of migraine in bipolar disorder. J Affect Disord 99:239–241, 1999
 
Malcolm R, Myrick H, Brady KT, et al: Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 10 (suppl):16–23, 2001
 
Malcolm R, Myrick LH, Veatch LM, et al: Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med 15:24–23, 2007
 
Mariani JJ, Rosenthal RN, Tross S, et al: A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict 15:76–84, 2006
[PubMed]
 
Mathew NT, Rapoport A, Saper J, et al: Efficacy of gabapentin in migraine prophylaxis. Headache 41:119–128, 2001
[PubMed]
 
McLean MJ: Gabapentin in the management of convulsive disorders. Epilepsia 40 (suppl 6):S39–S50, 1999
 
Mease PJ, Russell J, Arnold LM, et al: A randomized, double-blind, placebo-controlled phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502–514, 2008
[PubMed]
 
Miller RG, Moore D, Young LA, et al: Placebo-controlled trial of gabapentin in patients with ALS. Neurology 47:1383–1388, 1996
[PubMed]
 
Montgomery S: Pregabalin for the treatment of generalized anxiety disorder. Exp Opin Pharmacother 7:2139–2154, 2006
[PubMed]
 
Montgomery SA, Tobias K, Zornberg GL, et al: Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782, 2006
[PubMed]
 
Neurontin (gabapentin) package insert. Physicians' Desk Reference, 60th Edition. Montvale, NJ, Medical Economics Company, 2006
 
Obrocea GV, Dunn RM, Frye MA, et al: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 51:253–260, 2002
[PubMed]
 
Olson W, Gruenthal M, Muller ME, et al: Gabapentin for parkinsonism: a double-blind, placebo-controlled, cross-over trial. Am J Med 102:60–66, 1997
[PubMed]
 
Ondo W, Hunter C, Vuong KD, et al: Gabapentin for essential tremor: a multiple-dose, double-blind, placebo controlled trial. Mov Disord 15:678–682, 2000
[PubMed]
 
Pahwa R, Lyons K, Hubble JP, et al: Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 13:465–467, 1998
[PubMed]
 
Pande AC, Davidson JRT, Jefferson JW, et al: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348, 1999
[PubMed]
 
Pande AC, Crockatt JG, Janney CA, et al: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2(3 pt 2):249–255, 2000a
 
Pande AC, Pollack MH, Crockatt J, et al: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467–471, 2000b
 
Pande AC, Crockatt JG, Feltner DE, et al: Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533–540, 2003
[PubMed]
 
Pande AC, Feltner DE, Jefferson JW, et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141–149, 2004
[PubMed]
 
Petroff OA, Rothman Dl, Behar KL, et al: The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39:95–99, 1996
[PubMed]
 
Petty F, Kraemer GL, Dunnam D, et al: Plasma GABA in mood disorders. Psychopharmacol Bull 26:157–161, 1990
[PubMed]
 
Pinninti NR, Mahajan DS: Gabapentin-associated aggression. J Neuropsychiatry Clin Neurosci 13:424–429, 2001
[PubMed]
 
Pohl RB, Feltner DE, Rieve RR, et al: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BPI versus TID dosing. J Clin Psychopharmacology 25:151–158, 2005
[PubMed]
 
Pollack MH, Matthews M, Scott EL: Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155:992–993, 1998
[PubMed]
 
Rao ML, Clarenbach P, Vahlensieck M, et al: Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm 73:129–134, 1988
[PubMed]
 
Rice AS, Maton S, Postherpetic Neuralgia Study Group: Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94:215–224, 2001
[PubMed]
 
Rickels K, Pollack MH, Feltner DE, et al: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022–1030, 2005
[PubMed]
 
Rowbotham M, Harden N, Stacey B, et al: Gabapentin for the treatment of postherpetic neuralgia. JAMA 280:1837–1842, 1998
[PubMed]
 
Roy A, Dejong J, Ferraro T: CSF GABA in depressed patients and normal controls. Psychol Med 21:613–618, 1991
[PubMed]
 
Sabatowski R, Gálvez R, Cherry DA, et al: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109:26–35, 2004
[PubMed]
 
Sanacora G, Mason GF, Rothman DL, et al: Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56:1043–1047, 1999
[PubMed]
 
Sanacora G, Mason GF, Rothman DL, et al: Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159:663–665, 2002
[PubMed]
 
Schlicker E, Reimann W, Gothert M: Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung 35:1347–1349, 1985
[PubMed]
 
Short C, Cooke L: Hypomania induced by gabapentin. Br J Psychiatry 167:549, 1995
 
Singh L, Field MJ, Ferris P, et al: The antiepileptic agent gabapentin (Neurontin) processes anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 127:1–9, 1996
[PubMed]
 
Taylor CP, Vartanina MG, Andruszkiewiewicz R, et al: 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsants agents. Epilepsy Res 11:103–110, 1992
[PubMed]
 
Taylor CP, Gee NS, Su TZ, et al: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29:233–249, 1998
[PubMed]
 
Van Seventer R, Feister HA, Young JP, et al: Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week randomized trial. Curr Med Res Opin 222:375–384, 2006
 
Watson WP, Robinson E, Little HJ: The novel anticonvulsant gabapentin protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropsychopharmacology 36:1369–1375, 1997
[PubMed]
 
Weiss SR, Post RM: Kindling: separate vs shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 38:167–180, 1998
[PubMed]
 
Wolf SM, Shinnar S, Kang H et al: Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 36:1203–1205, 1996
 
Wolfe F, Smythe HA, Yunus MB, et al: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172, 1990
[PubMed]
 
Yatham LN, Kusumakar V, Calabrese JR, et al: Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 63:275–283, 2002
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
In regard to pharmacokinetics, gabapentin
2.
Gabapentin is approved by the U.S. Food and Drug Administration (FDA) to treat which of the following conditions?
3.
When used in the treatment of alcohol withdrawal syndrome, gabapentin has produced which of the following benefits?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 29.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 42.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 81.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 38.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 54.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation